Malondialdehyde level in chronic obstructive pulmonary disease exacerbations

Natalja Voskresenska; Julija Voicehovska; Aleksandra Vojcehovska; Grigorijs Orlikovs; Andrejs Skesters

doi:10.1183/13993003.congress-2015.OA2920

Malondialdehyde level in chronic obstructive pulmonary disease exacerbations

Natalja Voskresenska, Julija Voicehovska, Aleksandra Vojcehovska, Grigorijs Orlikovs, Andrejs Skesters

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased inflammation followed by oxidative stress (OS). Malondialdehyde (MDA) negatively correlation with PFT was demonstrated (Upasana J. et al. ERJ vol. 44 no. Suppl 58 P3958) In patients who survive their first COPD-related hospitalization up to 50% have been reported for re-admission within 6 months of discharge. Up to 84% of direct costs associated with COPD are due to inpatient hospitalizations.

Original language	English
Article number	OA2920
Journal	European Respiratory Journal
Volume	46
Issue number	S59
DOIs	https://doi.org/10.1183/13993003.congress-2015.OA2920
Publication status	Published - 1 Sep 2015
Event	European Respiratory Society International Congress - Amsterdam, Netherlands Duration: 26 Sep 2015 → 30 Sep 2015

Keywords

Biomarkers
COPD - exacerbations
Monitoring

Field of Science

3.2 Clinical medicine

Publication Type

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1183/13993003.congress-2015.OA2920

Cite this

@article{0b30499cc52647eea317709ba98b9234,

title = "Malondialdehyde level in chronic obstructive pulmonary disease exacerbations",

abstract = "Chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased inflammation followed by oxidative stress (OS). Malondialdehyde (MDA) negatively correlation with PFT was demonstrated (Upasana J. et al. ERJ vol. 44 no. Suppl 58 P3958) In patients who survive their first COPD-related hospitalization up to 50% have been reported for re-admission within 6 months of discharge. Up to 84% of direct costs associated with COPD are due to inpatient hospitalizations.",

keywords = "Biomarkers, COPD - exacerbations, Monitoring",

author = "Natalja Voskresenska and Julija Voicehovska and Aleksandra Vojcehovska and Grigorijs Orlikovs and Andrejs Skesters",

year = "2015",

month = sep,

day = "1",

doi = "10.1183/13993003.congress-2015.OA2920",

language = "English",

volume = "46",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "S59",

note = " European Respiratory Society International Congress, ERS ; Conference date: 26-09-2015 Through 30-09-2015",

}

TY - JOUR

T1 - Malondialdehyde level in chronic obstructive pulmonary disease exacerbations

AU - Voskresenska, Natalja

AU - Voicehovska, Julija

AU - Vojcehovska, Aleksandra

AU - Orlikovs, Grigorijs

AU - Skesters, Andrejs

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased inflammation followed by oxidative stress (OS). Malondialdehyde (MDA) negatively correlation with PFT was demonstrated (Upasana J. et al. ERJ vol. 44 no. Suppl 58 P3958) In patients who survive their first COPD-related hospitalization up to 50% have been reported for re-admission within 6 months of discharge. Up to 84% of direct costs associated with COPD are due to inpatient hospitalizations.

AB - Chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased inflammation followed by oxidative stress (OS). Malondialdehyde (MDA) negatively correlation with PFT was demonstrated (Upasana J. et al. ERJ vol. 44 no. Suppl 58 P3958) In patients who survive their first COPD-related hospitalization up to 50% have been reported for re-admission within 6 months of discharge. Up to 84% of direct costs associated with COPD are due to inpatient hospitalizations.

KW - Biomarkers

KW - COPD - exacerbations

KW - Monitoring

U2 - 10.1183/13993003.congress-2015.OA2920

DO - 10.1183/13993003.congress-2015.OA2920

M3 - Meeting Abstract

VL - 46

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - S59

M1 - OA2920

T2 - European Respiratory Society International Congress

Y2 - 26 September 2015 through 30 September 2015

ER -

Malondialdehyde level in chronic obstructive pulmonary disease exacerbations

Abstract

Keywords

Field of Science

Publication Type

Access to Document

Fingerprint

Cite this